NOBLEOAK LIFE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.6 AUD | +1.91% |
|
-3.03% | -3.61% |
| Feb. 28 | NobleOak Life Shares Add 7% Despite 55% Plunge in Fiscal H1 Profit | MT |
| Feb. 28 | Transcript : NobleOak Life Limited, H1 2024 Earnings Call, Feb 28, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- With a P/E ratio at 10.84 for the current year and 9.03 for next year, earnings multiples are highly attractive compared with competitors.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.61% | 91.4M | - | ||
| +10.87% | 98.91B | B- | ||
| +2.63% | 98.63B | B | ||
| -9.85% | 87.94B | B+ | ||
| +17.62% | 74.27B | D+ | ||
| +8.49% | 31.02B | B | ||
| +20.29% | 29.23B | B | ||
| +6.48% | 27.81B | A | ||
| +0.74% | 17.33B | C+ | ||
| -12.49% | 14.6B | B |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NOL Stock
- Ratings NobleOak Life Limited
